<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        42-5015-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZINOLE 15MG TABLET (30 tablets)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        248.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zinole tablets contain the active substance aripiprazole and belong to a group of medicines called<br />antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a<br />disease characterised by symptoms such as hearing, seeing or sensing things which are not there,<br />suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People<br />with this condition may also feel depressed, guilty, anxious or tense.<br />Zinole tablets are used to treat adults and adolescents aged 13 years and older who suffer from a<br />condition with symptoms such as feeling &quot;high&quot;, having excessive amounts of energy, needing much<br />less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. In<br />adults it also prevents this condition from returning in patients who have responded to the treatment<br />with Zinole tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Zinole tablets<br />&bull; if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in<br />section 6).<br />Warnings and precautions<br />Talk to your doctor before taking Zinole tablets if you suffer from<br />&bull; high blood sugar (characterised by symptoms such as excessive thirst, passing of large<br />amounts of urine, increase in appetite, and feeling weak) or family history of diabetes<br />&bull; seizure<br />&bull; involuntary, irregular muscle movements, especially in the face<br />&bull; cardiovascular diseases, family history of cardiovascular disease, stroke or &quot;mini&quot; stroke,<br />abnormal blood pressure<br />&bull; blood clots, or family history of blood clots, as antipsychotics have been associated with<br />formation of blood clots<br />&bull; past experience of excessive gambling<br />If you notice you are gaining weight, develop unusual movements, experience somnolence that<br />interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell<br />your doctor.<br />If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you<br />or your carer/relative should tell your doctor if you have ever had a stroke or &quot;mini&quot; stroke.<br />Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself.<br />Suicidal thoughts and behaviours have been reported during aripiprazole treatment.<br />Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever,<br />sweating, altered mental status, or very rapid or irregular heart beat.<br />Children and adolescents<br />Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is<br />safe and effective in these patients.<br />Other medicines and Zinole tablets<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines, including medicines obtained without a prescription.<br />Blood pressure-lowering medicines: aripiprazole may increase the effect of medicines used to lower<br />the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure<br />under control.<br />Taking Zinole tablets with some medicines may need to change your dose of aripiprazole. It is<br />especially important to mention the following to your doctor:<br />&bull; Medicines to correct heart rhythm<br />&bull; Antidepressants or herbal remedy used to treat depression and anxiety<br />&bull; Antifungal agents<br />&bull; Certain medicines to treat HIV infection<br />&bull; Anticonvulsants used to treat epilepsy<br />Medicines that increase the level of serotonin: triptans, tramadol, tryptophan, SSRIs (such as<br />paroxetine and fluoxetine), tricyclics (such as clomipramine, amitriptyline), pethidine, St John&rsquo;s Wort<br />and venlafaxine. These medicines increase the risk of side effects; if you get any unusual symptom<br />taking any of these medicines together with Zinole tablets, you should see your doctor.<br />Zinole tablets with food, drink and alcohol<br />Zinole tablets can be taken regardless of meals. Alcohol should be avoided.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor for advice before taking this medicine.<br />The following symptoms may occur in newborn babies, of mothers that have used aripiprazole in the<br />last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness,<br />sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these<br />symptoms you may need to contact your doctor.<br />Be sure to tell your doctor immediately if you are breast-feeding. If you are taking aripiprazole, you<br />should not breast-feed. Driving and using machines<br />Do not drive or use any tools or machines, until you know how aripiprazole affect you.<br />Zinole tablets contain lactose<br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor<br />before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor<br />or pharmacist if you are not sure.<br />The recommended dose for adults is 15 mg once a day. However your doctor may prescribe a<br />lower or higher dose to a maximum of 30 mg once a day.<br />Use in children and adolescents<br />This medicinal product may be started at a low dose with the oral solution (liquid) form.<br />The dose may be gradually increased to the recommended dose for adolescents of 10 mg once a<br />day. However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.<br />If you have the impression that the effects of your Zinole tablets are too strong or too weak, talk to<br />your doctor or pharmacist.<br />Try to take your Zinole tablets at the same time each day. It does not matter whether you take it<br />with or without food. Always take the tablet with water and swallow it whole.<br />Even if you feel better, do not alter or discontinue the daily dose of Zinole tablets without first<br />consulting your doctor.<br />If you take more Zinole tablets than you should<br />If you realise you have taken more Zinole tablets than your doctor has recommended (or if someone<br />else has taken some of your Zinole tablets), contact your doctor right away. If you cannot reach your<br />doctor, go to the nearest hospital and take the pack with you.<br />If you forget to take your Zinole tablets<br />If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one<br />day.<br />If you stop taking Zinole tablets<br />Do not stop your treatment just because you feel better. It is important that you carry on taking your<br />Zinole tablets for as long as your doctor has told you to.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Common<br />side effects (may affect up to 1 in 10 people):<br />&bull; diabetes mellitus,<br />&bull; difficulty sleeping,<br />&bull; feeling anxious,<br />&bull; feeling restless and unable to keep still, difficulty sitting still,<br />&bull; uncontrollable twitching, jerking or writhing movements, restless legs,<br />&bull; trembling,<br />&bull; headache,<br />&bull; tiredness,<br />&bull; sleepiness,<br />&bull; light-headedness,<br />&bull; shaking and blurred vision,<br />&bull; decreased number of or difficulty making bowel movements,<br />&bull; indigestion,<br />&bull; feeling sick,<br />&bull; more saliva in mouth than normal,<br />&bull; vomiting,<br />&bull; feeling tired.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />&bull; increased blood levels of the hormone prolactin,<br />&bull; too much sugar in the blood,<br />&bull; depression,<br />&bull; altered or increased sexual interest,<br />&bull; uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),<br />&bull; muscle disorder causing twisting movements (dystonia),<br />&bull; double vision,<br />&bull; fast heart beat,<br />&bull; a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,<br />&bull; hiccups.<br />The following side effects have been reported since the marketing of oral aripiprazole but the<br />frequency for them to occur is not known:<br />&bull; low levels of white blood cells,<br />&bull; low levels of blood platelets,<br />&bull; allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),<br />&bull; onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,<br />&bull; high blood sugar,<br />&bull; not enough sodium in the blood,<br />&bull; loss of appetite (anorexia),<br />&bull; weight loss,<br />&bull; weight gain,<br />&bull; thoughts of suicide, suicide attempt and suicide,<br />&bull; excessive gambling,<br />&bull; feeling aggressive,<br />&bull; agitation,<br />&bull; nervousness,<br />&bull; combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and<br />sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),<br />&bull; seizure,<br />&bull; serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness,<br />clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),<br />&bull; speech disorder,<br />&bull; sudden unexplained death,<br />&bull; life-threatening irregular heart beat,<br />&bull; heart attack,<br />&bull; slower heart beat, blood clots in the veins especially in the legs (symptoms include swelling,<br />pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain<br />and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately),<br />&bull; high blood pressure,<br />&bull; fainting,<br />&bull; accidental inhalation of food with risk of pneumonia (lung infection),<br />&bull; spasm of the muscles around the voice box,<br />&bull; inflammation of the pancreas,<br />&bull; difficulty swallowing,<br />&bull; diarrhoea,<br />&bull; abdominal discomfort,<br />&bull; stomach discomfort,<br />&bull; liver failure,<br />&bull; inflammation of the liver,<br />&bull; yellowing of the skin and white part of eyes,<br />&bull; reports of abnormal liver tests values,<br />&bull; skin rash,<br />&bull; sensitivity to light,<br />&bull; baldness,<br />&bull; excessive sweating,<br />&bull; abnormal muscle breakdown which can lead to kidney problems,<br />&bull; muscle pain,<br />&bull; stiffness,<br />&bull; involuntary loss of urine (incontinence),<br />&bull; difficulty in passing urine,<br />&bull; withdrawal symptoms in newborn babies in case of exposure during pregnancy,<br />&bull; prolonged and/or painful erection,<br />&bull; difficulty controlling core body temperature or overheating,<br />&bull; chest pain,<br />&bull; swelling of hands, ankles or feet,<br />&bull; in blood tests: fluctuating blood sugar, increased glycosylated haemoglobin.<br />In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In<br />addition, cases of stroke or &quot;mini&quot; stroke have been reported.<br />Additional side effects in children and adolescents<br />Adolescents aged 13 years and older experienced side effects that were similar in frequency and type<br />to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness,<br />and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth,<br />increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of<br />the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were<br />common (greater than 1 in 100 patients).<br />Reporting of side effects<br />If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this<br />leaflet. You can also report side effects directly (see details below). By reporting side effects, you can<br />help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry<br />date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is aripiprazole. Each tablet contains 15 mg of aripiprazole.<br />&bull; The other ingredients are lactose monohydrate, maize starch pregelatinized, povidone,<br />microcrystalline cellulose, croscarmellose sodium, magnesium stearate and yellow iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zinole 15 mg tablets are yellow, cylindrical, biconvex and embossed with “15” on one side.
Zinole 15 mg is supplied in blister packs containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LABORATORIOS CINFA, S.A.<br />Olaz-Chipi,10. Pol&iacute;gono Industrial Areta,<br />31620 Huarte-Pamplona (Navarra) &ndash; Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2016

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص زينول على المادة الفعالة أريبيبرازول وتنتمي إلى مجموعة من الأدوية تُعرف باسم مضادات الذُهان. تُستخدم هذه الأدوية لعلاج البالغين والمراهقين الذين يبلغون 15 عاماً فأكثر والذين يعانون من مرض تُصاحبه أعراض مثل سماع أو رؤية أو الشعور بأشياء ليس لها وجود، والارتياب، والاعتقادات الخاطئة، &nbsp;و عدم ترابط السلوك والكلام، تبلد المشاعر. قد يشعر الأشخاص المصابون بهذا المرض بالاكتئاب، أو الذنب، أو القلق، أو التوتر.</p><p>تُستخدم أقراص زينول لعلاج البالغين والمراهقين الذين يبلغون 15 عاماً فأكثر والذين يعانون من مرض تُصاحبه أعراض مثل الشعور &quot;بالنشوة&quot;، والشعور بطاقة ونشاط هائلين، والحاجة إلى عدد ساعات نوم أقل من المعتاد، والتحدث بسرعة شديدة مع توارد أفكار سريعة، وسرعة الانفعال في بعض الأحيان. تعمل أقراص زينول على الحيلولة من إصابة المرضى البالغين الذين استجابوا للعلاج بأقراص زينول بهذه الحالة مرة أخرى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أقراص زينول في الحالات التالية:</strong></p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية لمادة أريبيبرازول أو أي من مكونات الدواء الأخرى (المدرجة في قسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول أقراص زينول إذا كنت تعاني من:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم (تصاحبه أعراض مثل: العطش الشديد، وإخراج كمية كبيرة من البول، وزيادة الشهية، والشعور بالوهن والضعف)، أو كان لديك تاريخ عائلي من الإصابة بمرض السكري.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنجية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات عضلية لا إرادية غير منتظمة، وخاصة في الوجه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب، أو تاريخ عائلي من الإصابة بالأمراض القلبية، والسكتة الدماغية، أو السكتة الدماغية البسيطة، وضغط الدم الغير طبيعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية، أو تاريخ عائلي من الإصابة بالجلطات الدموية، فطالما ارتبطت مضادات الذُهان بتكون الجلطات الدموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة من قبل بمرض المقامرة المرضية.</p><p dir="RTL">إذا لاحظت أنك تكتسب وزناً زائداً، أو ظهر عليك حركات غير طبيعية، أو تشعر بنعاس شديد يحول دون قيامك بالأنشطة اليومية الطبيعية، أو شعرت بصعوبة في التنفس أو أعراض حساسية، فأخبر طبيبك.</p><p dir="RTL">إذا كنت مريضاُ كبيراً في السن وتعاني من الخرف (فقدان الذاكرة والقدرات العقلية الأخرى)، يجب عليك أنت أو القائم على رعايتك/أحد أقاربك إخبار الطبيب إذا كنت قد أُصبت من قبل بسكتة دماغية أو سكتة دماغية &quot;بسيطة&quot;.</p><p dir="RTL">أخبر طبيبك على الفور إذا كان ينتابك أي أفكار أو مشاعر عن إيذاء نفسك. لقد تم الإبلاغ عن ظهور أفكار وسلوكيات انتحارية خلال فترة العلاج بدواء أريبيبرازول.</p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تعاني من تيبس أو تصلب في العضلات مصحوباً بحرارة مرتفعة، أو التعرق، أو حالة عقلية متغيرة، أو ضربات قلب سريعة أو غير منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تجنب إعطاء الأطفال والمراهقين الذين لم يبلغوا 13 عاماً هذا الدواء؛ نظراً لعدم التأكد من كون هذا الدواء آمناً وفعالاً لإعطائه لهؤلاء المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، ويشمل هذا الأدوية التي اشتريتها دون وصفة طبية.</p><p dir="RTL">الأدوية الخافضة لضغط الدم: قد يزيد أريبيبرازول من تأثير الأدوية المستخدمة لخفض ضغط الدم. تأكد من إخبار طبيبك إذا كنت تتناول دواء لضبط مستوى ضغط الدم.</p><p dir="RTL">قد يؤدي تناول أقراص زينول مع بعض الأدوية إلى ضرورة تغيير جرعتك من أريبيبرازول. من المهم أن تذكر لطبيبك الأدوية التالية:</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تنظيم ضربات القلب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب، أو العلاجات العشبية المستخدمة لعلاج الاكتئاب والقلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الفطريات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المتخصصة في علاج عدوى فيروس العوز المناعي البشري.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الصرع التي تستخدم لعلاج الصرع.</p><p dir="RTL">الأدوية التي تزيد مستوى السيروتونين: التريبتانات، والترامادول، والتريبتوفان،&nbsp; ومثبطات استرداد السيروتونين الانتقائية (مثل باروكسيتين وفلوكسيتين)، ومضادات الاكتئاب الثلاثية الحلقات (مثل كلوميبرامين، أميتريبتيلين)، وبيثيدين، ونبتة سانت جونز، وفينلافاكسين. تزيد هذه الأدوية خطر الإصابة بالآثار الجانبية؛ إذا ظهر عليك أي عرض غير معتاد عند تناول أي من هذه الأدوية مع أقراص زينول، يجب عليك رؤية الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أقراص زينول مع الطعام والشراب والكحول </strong></p><p dir="RTL">يمكن تناول أقراص زينول مع الطعام أو بدونه. يجب تجنب تناول الكحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين أو تعتقدين أنك حامل أو تخططين لذلك فاستشيري طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">وقد تظهر الأعراض التالية مع الأطفال الحديثي الولادة حال تناول الأم أريبيبرازول في الفترة الأخيرة من الحمل (الأشهر الثلاثة الأخيرة من الحمل): ارتعاش العضلات وتصلبها، و/أو الضعف عام، والشعور بالنعاس، والقلق، واضطرابات في التنفس، وصعوبة في الإرضاع. حال ظهور أي من هذه الأعراض على الطفل الحديث الولادة، يجب الاتصال بالطبيب على الفور.</p><p dir="RTL">تأكدي من إخبار طبيبك على الفور إذا كنت ترضعين طفلك طبيعياً. إذا كنت تتناولين أريبيبرازول، يجب عليك تجنب الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">تجنب القيادة أو استخدام أي أدوات أو آلات، حتى تعلم تأثير تناول أريبيبرازول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحتوي أقراص زينول على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك تعاني من حساسية لبعض أنواع السكر فاستشر طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً حسب وصف الطبيب أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعة الموصى بها للبالغين هي 15 ملجم مرة واحدة يومياً</strong>. بالرغم من ذلك، قد يصف لك طبيبك جرعة أقل أو أكبر بحيث لا تزيد على 30 ملجم مرة واحدة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام من قِبل الأطفال والمراهقين</strong></p><p dir="RTL">قد تبدأ تناول هذا المنتج الدوائي بجرعة منخفضة في شكل محلول (سائل) يؤخذ عن طريق الفم.</p><p dir="RTL">قد يزيد طبيبك الجرعة تدريجياً حتى تصل إلى الجرعة الموصى بها للمراهقين والتي تبلغ 10 ملجم مرة واحدة يومياً. بالرغم من ذلك، قد يصف لك طبيبك جرعة أقل أو أكبر بحيث لا تزيد على 30 ملجم مرة واحدة يومياً.</p><p dir="RTL">إذا كان لديك انطباع بأن تأثير أقراص زينول قوي جداً أو ضعيف جداً فاستشر الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حاول تناول جرعتك اليومية من أقراص زينول في نفس الوقت من كل يوم</strong>. يمكن تناول الأقراص مع الطعام أو بدونه. تناول القرص دائماً مع الماء وابتلعه كاملاً.</p><p dir="RTL"><strong>حتى وإن كنت تشعر بتحسن</strong>، لا تقوم بتغيير الجرعة اليومية من أقراص زينول أو إيقافها دون استشارة طبيبك أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول جرعة زائدة من أقراص زينول</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من أقراص زينول تفوق الجرعة الموصى بها من قبل طبيبك (أو إذا تناول شخص آخر بعض أقراص زينول الخاصة بك) اتصل بطبيبك على الفور. إذا لم تتمكن من الوصول إلى طبيبك، فتوجه إلى أقرب مستشفى واصطحب علبة الدواء معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أقراص زينول</strong></p><p dir="RTL">إذا نسيت تناول إحدى الجرعات، فتناول الجرعة الفائتة بمجرد تذكرها ولكن لا تتناول جرعتين في نفس اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أقراص زينول</strong></p><p dir="RTL">لا تتوقف عن إتمام العلاج لمجرد الشعور بتحسن. من المهم الاستمرار في تناول أقراص زينول حسب وصف الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا الدواء فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر في شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتململ، وعدم القدرة على الاحتفاظ بالهدوء، وصعوبة في الجلوس هادئاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية، أو اهتزازات، أو حركات ملتوية لا إرادية، وتململ الساقين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش ورؤية ضبابية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حركة الأمعاء أو صعوبة حركتها.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز اللعاب داخل الفم أكثر من المعتاد.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب.</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تؤثر في شخص واحد من كل 100 شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات هرمون البرولاكتين في الدم.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في الدم.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في الرغبة الجنسية أو زيادتها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية للفم واللسان والأطراف (خلل الحركة المتأخر).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب العضلات المسبب لحركات التوائية (خلل التوتر).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية المزدوجة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم عند الوقوف مما يسبب الشعور بالدوار، أو الدوخة، أو الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفواق.</p><p dir="RTL">لقد تم الإبلاغ عن ظهور الآثار الجانبية التالية منذ التسويق لدواء أريبيبرازول الذي يؤخذ عن طريق الفم إلا أن معدل تكرار حدوثها غير معروف:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم البيضاء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية (مثل: تورم الفم واللسان والوجه والحلق، والحكة، الشرى).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمرض السكري أو التدهور في الحالة، والحماض الكيتوني السكري (وجود الكيتونات في الدم والبول)، أو الغيبوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الصوديوم في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية (قلة الشهية للطعام).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية، محاولة الانتحار و الانتحار.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المقامرة المرضية.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلوك العدواني .</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة التوتر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة من الآثار الجانبية التي تحدث معاً مثل: الحمى، وتيبس العضلات، ومعدل التنفس السريع، والتعرق، وقلة الإدراك، وتغيرات مفاجئة في ضغط الدم، ومعدل ضربات القلب، والإغماء (المتلازمة الخبيثة للدواء المضاد للذهان).</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات التشنجية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة سيروتونين (تفاعل قد يؤدي إلى الشعور بالسعادة الغامرة، أو الدوار، أو الخرف، أو التململ، أو الشعور بالثمل، الحمى، أو التعرق، أو تيبس العضلات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الكلام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت مفاجئ غير محدد السبب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير منتظمة مهددة للحياة.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزمة القلبية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في معدل ضربات القلب، وجلطات دموية في الأوردة وخاصة في الساقين (وتشمل الأعراض تورم الساق واحمرارها، والشعور بألم فيها)، والتي قد تنتقل خلال الأوعية الدموية ومنها إلى الرئتين مسببة ألماً في الصدر وصعوبة في التنفس (إذا لاحظت أي من هذه الأعراض فاحصل على الاستشارة الطبية على الفور).</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دخول الطعام في مجرى الهواء عن طريق الخطأ مع احتمال الإصابة بالتهاب رئوي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص العضلات المحيطة بالحنجرة.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في المعدة.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد وبياض العين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيم غير طبيعية في فحوص الكبد.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية للضوء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلل غير طبيعي في الأنسجة العضلية مما قد يؤدي إلى مشكلات في الكُلى.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزول البول بشكل لا إرادي (سلس البول).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انسحابية في الأطفال الحديثي الولادة في حال تناول الدواء خلال فترة الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب طويل المدة و/أو مصحوب بألم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التحكم في درجة حرارة الجسم الداخلية أو ارتفاع درجة حرارة الجسم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر.</p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الكاحلين أو القدمين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اختبارات الدم: عدم انتظام مستوى السكر في الدم وزيادة الهيموغلوبين الغليكوزيلاتي.</p><p dir="RTL">في المرضى كبار السن المصابين بالخرف، تم الإبلاغ عن عدد أكبر من حالات الوفاة خلال فترة العلاج بأريبيبرازول. كما تم الإبلاغ عن حدوث حالات سكتة دماغية أو سكتة دماغية بسيطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الإضافية في الأطفال والمراهقين</strong></p><p dir="RTL">ظهر على المراهقين الذين يبلغون 13 عاماً فأكثر آثار جانبية مشابهة لتلك الآثار الجانبية التي تظهر لدى البالغين من حيث معدل التكرار والنوع باستثناء الشعور بالنعاس، والتشنجات، أو الاهتزازات العضلية اللاإرادية، والتململ، والشعور بالتعب والتي كانت شديدة الشيوع (أكثر من مريض واحد من كل 10 أشخاص) وكان الشعور بألم في أعلى البطن، وجفاف الفم، وزيادة معدل ضربات القلب، وزيادة الوزن، وزيادة الشهية، واهتزاز العضلات، وحركات الأطراف اللاإرادية، والشعور بالدوار -وخاصة عند النهوض من وضع الاستلقاء أو وضع الجلوس- من الآثار الجانبية الشائعة (أكثر من مريض واحد من كل 100 مريض).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن ظهور آثار جانبية</strong></p><p dir="RTL">إذا شعرت بأي آثار جانبية فتحدث إلى طبيبك. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). يمكنكم المساهمة في تقديم المزيد من المعلومات المتعلقة بسلامة هذا الدواء وذلك بإبلاغنا عن ظهور آثار جانبية له.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن مرأى و متناول الأطفال.</p><p dir="RTL">لا يُستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة بعد كلمة &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة تقل عن 30 ْم.</p><p dir="RTL">ينبغي عدم التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات أقراص زينول</strong></p><p dir="RTL">&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أريبيبرازول. يحتوي كل قرص على 15 ملجم من أريبيبرازول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: مونوهيدرات اللاكتوز، ونشا ذرة بدون جيلاتين، وبوفيدون، وسليلوز دقيق البللورات، وكروس كارميلوز الصوديوم، وستيارات الماغنسيوم، وأكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر زينول 15 ملجم في شكل أقراص أسطوانية، محدبة الوجهين ذات لون أصفر محفور على أحد جانبيها &ldquo;15&rdquo;.</p><p dir="RTL">تتوفر أقراص زينول 15 ملجم في شرائط مغلفة تحتوي على 30 قرصاً.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية،</p><p dir="RTL">31620 أوارتي-بامبلونا (نافارا) - إسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُجريت آخر مراجعة لهذه النشرة في سبتمبر 2016 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Zinole 15 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zinole 15 mg tablets
Each tablet contains 15 mg of aripiprazole.
Excipient with known effect 179.3 mg lactose per tablet and maize starch pregelatinized.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Zinole 15 mg tablets are yellow, cylindrical, biconvex and embossed with “15” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinole is indicated for the treatment of schizophrenia in adults and in adolescents aged 15<br />years and older.<br />Zinole is indicated for the treatment of moderate to severe manic episodes in Bipolar I<br />Disorder and for the prevention<br />of a new manic episode in adults who experienced predominantly manic episodes and whose<br />manic episodes responded to aripiprazole treatment (see section 5.1).<br />Zinole is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in<br />Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />Schizophrenia: the recommended starting dose for Zinole is 10 or 15 mg/day with a<br />maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to<br />meals. Zinole is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses<br />higher than a daily dose of 15 mg has not been demonstrated although individual patients may<br />benefit from a higher dose. The maximum daily dose should not exceed 30 mg.<br />Manic episodes in Bipolar I Disorder: the recommended starting dose for Zinole is 15 mg<br />administered on a once-a- day schedule without regard to meals as monotherapy or<br />combination therapy (see section 5.1). Some patients may benefit from a higher dose. The<br />maximum daily dose should not exceed 30 mg.<br />Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of<br />manic episodes in patients, who have been receiving aripiprazole as monotherapy or<br />combination therapy, continue therapy at the same dose.<br />Adjustments of daily dosage, including dose reduction should be considered on the basis of<br />clinical status.<br />Special populations<br />Paediatric population<br />Schizophrenia in adolescents aged 15 years and older: the recommended dose for Zinole is 10<br />mg/day administered on a once-a-day schedule without regard to meals. Treatment should be<br />initiated at 2 mg (using aripiprazole oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2<br />additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent<br />dose increases should be administered in 5 mg increments without exceeding the maximum<br />daily dose of 30 mg (see section 5.1). Zinole is effective in a dose range of 10 to 30 mg/day.<br />Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated<br />although individual patients may benefit from a higher dose.<br />Aripiprazole is not recommended for use in patients with schizophrenia below 15 years of age<br />due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).<br />Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the<br />recommended dose for Zinole is 10 mg/day administered on a once-a-day schedule without<br />regard to meals. Treatment should be initiated at 2 mg (using aripiprazole oral solution 1<br />mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose<br />of 10 mg. The treatment duration should be the minimum necessary for symptom control and<br />must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has<br />not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher<br />incidence of significant undesirable effects including EPS related events, somnolence, fatigue<br />and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used<br />in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1).<br />Younger patients are at increased risk of experiencing adverse events associated with<br />aripiprazole. Therefore, aripiprazole is not recommended for use in patients below 13 years of<br />age (see sections 4.8 and 5.1).<br />Irritability associated with autistic disorder: the safety and efficacy of aripiprazole in children<br />and adolescents aged below 18 years have not yet been established. Currently available data<br />are described in section 5.1 but no recommendation on a posology can be made.<br />Tics associated with Tourette&#39;s disorder: the safety and efficacy of aripiprazole in children and<br />adolescents 6 to 18 years of age have not yet been established. Currently available data are<br />described in section 5.1 but no recommendation on a posology can be made.<br />Hepatic impairment<br />No dosage adjustment is required for patients with mild to moderate hepatic impairment. In<br />patients with severe hepatic impairment, the data available are insufficient to establish<br />recommendations. In these patients dosing should be managed cautiously. However, the<br />maximum daily dose of 30 mg should be used with caution in patients with severe hepatic<br />impairment (see section 5.2).<br />Renal impairment<br />No dosage adjustment is required in patients with renal impairment.<br />Elderly<br />The effectiveness of aripiprazole in the treatment of schizophrenia and Bipolar I Disorder in<br />patients aged 65 years and older has not been established. Owing to the greater sensitivity of<br />this population, a lower starting dose should be considered when clinical factors warrant (see<br />section 4.4).<br />Gender<br />No dosage adjustment is required for female patients as compared to male patients (see section<br />5.2).<br />Smoking status<br />According to the metabolic pathway of aripiprazole no dosage adjustment is required for<br />smokers (see section 4.5).<br />Dose adjustments due to interactions<br />When concomitant administration of potent CYP3A4 or CYP2D6 inhibitors with aripiprazole<br />occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is<br />withdrawn from the combination therapy, aripiprazole dose should then be increased (see<br />section 4.5).<br />When concomitant administration of potent CYP3A4 inducers with aripiprazole occurs, the<br />aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the<br />combination therapy, the aripiprazole dose should then be reduced to the recommended dose<br />(see section 4.5).<br />Method of administration<br />Zinole is for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take<br />several days to some weeks. Patients should be closely monitored throughout this period.<br />Suicidality<br />The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and<br />in some cases has been reported early after initiation or switch of antipsychotic treatment,<br />including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients<br />should accompany antipsychotic therapy.<br />Results of an epidemiological study suggested that there was no increased risk of suicidality<br />with aripiprazole compared to other antipsychotics among adult patients with schizophrenia<br />or bipolar disorder. There are insufficient paediatric data to evaluate this risk in younger<br />patients (below 18 years of age), but there is evidence that the risk of suicide persists beyond<br />the first 4 weeks of treatment for atypical antipsychotics, including aripiprazole.<br />Cardiovascular disorders<br />Aripiprazole should be used with caution in patients with known cardiovascular disease<br />(history of myocardial infarction or ischaemic heart disease, heart failure, or conduction<br />abnormalities), cerebrovascular disease, conditions which would predispose patients to<br />hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal<br />products) or hypertension, including accelerated or malignant. Cases of venous<br />thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since<br />patients treated with antipsychotics often present with acquired risk factors for VTE, all<br />possible risk factors for VTE should be identified before and during treatment with aripiprazole<br />and preventive measures undertaken.<br />QT prolongation<br />In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo.<br />As with other antipsychotics, aripiprazole should be used with caution in patients with a<br />family history of QT prolongation (see section 4.8).<br />Tardive dyskinesia<br />In clinical trials of one year or less duration, there were uncommon reports of treatment<br />emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive<br />dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be<br />considered (see section 4.8). These symptoms can temporally deteriorate or can even arise<br />after discontinuation of treatment.<br />Other extrapyramidal symptoms<br />In paediatric clinical trials of aripiprazole akathisia and parkinsonism were observed. If signs<br />and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close<br />clinical monitoring should be considered.<br />Neuroleptic Malignant Syndrome (NMS)<br />NMS is a potentially fatal symptom complex associated with antipsychotic medicinal<br />products. In clinical trials, rare cases of NMS were reported during treatment with<br />aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental<br />status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia,<br />diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine<br />phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated<br />creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have<br />also been reported. If a patient develops signs and symptoms indicative of NMS, or presents<br />with unexplained high fever without additional clinical manifestations of NMS, all<br />antipsychotic active substances, including aripiprazole, must be discontinued.<br />Seizure<br />In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole.<br />Therefore, aripiprazole should be used with caution in patients who have a history of seizure<br />disorder or have conditions associated with seizures (see section 4.8).<br />Elderly patients with dementia-related psychosis Increased mortality<br />In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of<br />aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease, patients<br />treated with aripiprazole were at increased risk of death compared to placebo. The rate of<br />death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group.<br />Although the causes of deaths were varied, most of the deaths appeared to be either<br />cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see<br />section 4.8).<br />Cerebrovascular adverse reactions<br />In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack),<br />including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years).<br />Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions<br />compared with 0.6 % of placebo-treated patients in these trials. This difference was not<br />statistically significant. However, in one of these trials, a fixed-dose trial, there was a<br />significant dose response relationship for cerebrovascular adverse reactions in patients treated<br />with aripiprazole (see section 4.8).<br />Aripiprazole is not indicated for the treatment of dementia-related psychosis.<br />Hyperglycaemia and diabetes mellitus<br />Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar<br />coma or death, has been reported in patients treated with atypical antipsychotic medicinal<br />products, including aripiprazole. Risk factors that may predispose patients to severe<br />complications include obesity and family history of diabetes. In clinical trials with<br />aripiprazole, there were no significant differences in the incidence rates of<br />hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia<br />laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related<br />adverse reactions in patients treated with aripiprazole and with other atypical antipsychotic<br />medicinal products are not available to allow direct comparisons. Patients treated with any<br />antipsychotic medicinal products, including aripiprazole, should be observed for signs and<br />symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and<br />patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored<br />regularly for worsening of glucose control (see section 4.8).<br />Hypersensitivity<br />As with other medicinal products, hypersensitivity reactions, characterised by allergic<br />symptoms, may occur with aripiprazole (see section 4.8).<br />Weight gain<br />Weight gain is commonly seen in schizophrenic and bipolar mania patients due to<br />co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style,<br />and might lead to severe complications. Weight gain has been reported post-marketing among<br />patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors<br />such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole<br />has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In<br />clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be<br />associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in<br />adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction<br />should be considered (see section 4.8).<br />Dysphagia<br />Oesophageal dysmotility and aspiration have been associated with antipsychotic medicinal<br />product use, including aripiprazole. Aripiprazole and other antipsychotic active substances<br />should be used cautiously in patients at risk for aspiration pneumonia.<br />Pathological gambling<br />Post-marketing reports of pathological gambling have been reported among patients prescribed<br />aripiprazole, regardless<br />of whether these patients had a prior history of gambling. Patients with a prior history of<br />pathological gambling may be at increased risk and should be monitored carefully (see section<br />4.8).<br />Lactose<br />Zinole tablets contain lactose. Patients with rare hereditary problems of galactose intolerance,<br />the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.<br />Patients with ADHD comorbidity<br />Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety<br />data are available on concomitant use of aripiprazole and stimulants; therefore, extreme<br />caution should be taken when these medicinal products are co-administered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its &alpha;1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the<br />effect of certain antihypertensive agents.<br />Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is<br />taken in combination with alcohol or other CNS medicinal products with overlapping adverse<br />reactions such as sedation (see section 4.8).<br />If aripiprazole is administered concomitantly with medicinal products known to cause QT<br />prolongation or electrolyte imbalance, caution should be used.<br />Potential for other medicinal products to affect aripiprazole<br />A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption<br />but this effect is deemed not clinically relevant. Aripiprazole is metabolised by multiple<br />pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no<br />dosage adjustment is required for smokers.<br />Quinidine and other CYP2D6 inhibitors<br />In a clinical trial in healthy subjects, a potent inhibitor of CYP2D6 (quinidine) increased<br />aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of<br />dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.<br />Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when<br />concomitant administration of aripiprazole with quinidine occurs. Other potent inhibitors of<br />CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and<br />similar dose reductions should therefore be applied.<br />Ketoconazole and other CYP3A4 inhibitors<br />In a clinical trial in healthy subjects, a potent inhibitor of CYP3A4 (ketoconazole) increased<br />aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of<br />dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor<br />metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma<br />concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.<br />When considering concomitant administration of ketoconazole or other potent CYP3A4<br />inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the<br />patient. When concomitant administration of ketoconozole with aripiprazole occurs,<br />aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other<br />potent inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, may be<br />expected to have similar effects and similar dose reductions should therefore be applied.<br />Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should<br />be increased to the level prior to the initiation of the concomitant therapy.<br />When weak inhibitors of CYP3A4 (e.g., diltiazem or escitalopram) or CYP2D6 are used<br />concomitantly with aripiprazole, modest increases in aripiprazole concentrations might be<br />expected.<br />Carbamazepine and other CYP3A4 inducers<br />Following concomitant administration of carbamazepine, a potent inducer of CYP3A4, the<br />geometric means of Cmax and AUC for aripiprazole were 68 % and 73 % lower, respectively,<br />compared to when aripiprazole (30 mg) was administered alone. Similarly, for<br />dehydro-aripiprazole the geometric means of Cmax and AUC after carbamazepine<br />co-administration were 69 % and 71 % lower, respectively, than those following treatment<br />with aripiprazole alone.<br />Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs<br />with carbamazepine. Other potent inducers of CYP3A4 (such as rifampicin, rifabutin,<br />phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be<br />expected to have similar effects and similar dose increases should therefore be applied. Upon<br />discontinuation of potent CYP3A4 inducers, the dosage of aripiprazole should be reduced to<br />the recommended dose.<br />Valproate and lithium<br />When either valproate or lithium were administered concomitantly with aripiprazole, there was<br />no clinically significant change in aripiprazole concentrations.<br />Serotonin syndrome<br />Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible<br />signs and symptoms for this condition can occur especially in cases of concomitant use with<br />other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that<br />are known to increase aripiprazole concentrations (see section 4.8).<br />Potential for aripiprazole to affect other medicinal products<br />In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the<br />metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9<br />(warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally,<br />aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2- mediated<br />metabolism in vitro. Thus, aripiprazole is unlikely to cause clinically important medicinal<br />product interactions mediated by these enzymes.<br />When aripiprazole was administered concomitantly with either valproate, lithium or<br />lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine<br />concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital<br />anomalies have been reported; however, causal relationship with aripiprazole could not be<br />established. Animal studies could not exclude potential developmental toxicity (see section<br />5.3). Patients should be advised to notify their physician if they become pregnant or intend to<br />become pregnant during treatment with aripiprazole. Due to insufficient safety information in<br />humans and concerns raised by animal reproductive studies, this medicinal product should not<br />be used in pregnancy unless the expected benefit clearly justifies the potential risk to the<br />foetus.<br />Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of<br />pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal<br />symptoms that may vary in severity and duration following delivery. There have been reports<br />of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding<br />disorder. Consequently, newborn infants should be monitored carefully.<br />Breast-feeding<br />Aripiprazole is excreted in human milk. Patients should be advised not to breast feed if they<br />are taking aripiprazole.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.7 Effects on ability to drive and use machines<br />As with other antipsychotics, patients should be cautioned about operating hazardous<br />machines, including motor vehicles, until they are reasonably certain that aripiprazole does<br />not affect them adversely. Some paediatric patients with Bipolar I Disorder have an increased<br />incidence of somnolence and fatigue (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions in placebo-controlled trials are akathisia and<br />nausea each occurring in more than 3 % of patients treated with oral aripiprazole.<br />Tabulated list of adverse reactions<br />All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge;<br />1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare<br />(&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each<br />frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />The frequency of adverse reactions reported during post-marketing use cannot be determined as<br />they are derived from spontaneous reports. Consequently, the frequency of these adverse events<br />is qualified as &quot;not known&quot;<br />Common Uncommon Not known<br />Blood and lymphatic<br />system disorders<br />Leukopenia Neutropenia<br />Thrombocytopenia<br />Immune system disorders Allergic reaction (e.g.<br />anaphylactic reaction,<br />angioedema including<br />swollen tongue, tongue<br />oedema, face oedema,<br />pruritus, or urticaria)<br />Endocrine disorders Hyperprolactinaemia Diabetic hyperosmolar<br />coma Diabetic<br />ketoacidosis<br />Hyperglycaemia<br />Metabolism and nutrition<br />disorders<br />Diabetes mellitus Hyperglycaemia Hyponatremia Anorexia<br />Weight decreased<br />Weight gain<br />Psychiatric disorders Insomnia Anxiety<br />Restlessness<br />Depression,<br />Hypersexuality<br />Suicide attempt, suicidal<br />ideation and completed<br />suicide (see section 4.4)<br />Pathological gambling<br />Aggression<br />Agitation<br />Nervousness<br />Nervous system disorders Akathisia<br />Extrapyramidal<br />disorder Tremor<br />Headache Sedation<br />Somnolence<br />Dizziness<br />Tardive dyskinesia<br />Dystonia<br />Neuroleptic Malignant<br />Syndrome (NMS)<br />Grand mal convulsion<br />Serotonin syndrome<br />Speech disorder<br />Eye disorders Vision blurred Diplopia<br />Cardiac disorders Tachycardia Sudden unexplained death<br />Torsades de pointes<br />QT prolongation<br />Ventricular arrhythmias<br />Cardiac arrest<br />Bradycardia<br />Vascular disorders Orthostatic<br />hypotension<br />Venous thromboembolism<br />(including pulmonary<br />embolism and deep vein<br />thrombosis)<br />Hypertension Syncope<br />Respiratory, thoracic and<br />mediastinal disorders<br />Hiccups Aspiration pneumonia<br />Laryngospasm<br />Oropharyngeal spasm<br />Gastrointestinal disorders Constipation<br />Dyspepsia Nausea<br />Salivary<br />hypersecretion<br />Vomiting<br />Pancreatitis Dysphagia<br />Diarrhoea<br />Abdominal discomfort<br />Stomach discomfort<br />Hepatobiliary disorders Hepatic failure Hepatitis<br />Jaundice<br />Increased Alanine<br />Aminotransferase (ALT)<br />Increased Aspartate<br />Aminotransferase (AST)<br />Increased Gamma<br />Glutamyl Transferase<br />(GGT)<br />Increased alkaline<br />phosphatase<br />Skin and subcutaneous<br />tissue disorders<br />Rash<br />Photosensitivity reaction<br />Alopecia<br />Hyperhidrosis<br />Musculoskeletal and<br />connective tissue disorders<br />Rhabdomyolysis Myalgia<br />Stiffness<br />Renal and urinary<br />disorders<br />Urinary incontinence<br />Urinary retention<br />Pregnancy, puerperium<br />and perinatal conditions<br />Drug withdrawal<br />syndrome neonatal (see<br />section 4.6)<br />Reproductive system and<br />breast disorders<br />Priapism<br />General disorders and<br />administration site<br />conditions<br />Fatigue Temperature regulation<br />disorder (e.g.<br />hypothermia, pyrexia)<br />Chest pain<br />Peripheral oedema<br />Investigations Blood glucose increased<br />Glycosylated<br />haemoglobin increased<br />Blood glucose fluctuation<br />Increased creatine<br />phosphokinase<br />Description of selected adverse reactions<br />Extrapyramidal symptoms (EPS)<br />Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an<br />overall-lower incidence (25.8<br />%) of EPS including parkinsonism, akathisia, dystonia and dyskinesia compared with those<br />treated with haloperidol (57.3 %). In a long term 26-week placebo-controlled trial, the<br />incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated<br />patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for<br />aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.<br />Manic episodes in Bipolar I Disorder: in a 12-week controlled trial, the incidence of EPS was<br />23.5 % for aripiprazole- treated patients and 53.3 % for haloperidol-treated patients. In another<br />12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6<br />% for those treated with lithium. In the long term 26-week maintenance phase of a<br />placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and<br />15.7 % for placebo-treated patients.<br />Akathisia<br />In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with<br />aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was<br />6.2 % with aripiprazole and 3.0 % with placebo.<br />Dystonia<br />Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may<br />occur in susceptible individuals during the first few days of treatment. Dystonic symptoms<br />include: spasm of the neck muscles, sometimes progressing to tightness of the throat,<br />swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these<br />symptoms can occur at low doses, they occur more frequently and with greater severity with<br />high potency and at higher doses of first generation antipsychotic medicinal products. An<br />elevated risk of acute dystonia is observed in males and younger age groups.<br />Prolactin<br />In clinical trials for the approved indications and post-marketing, both increase and decrease in<br />serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).<br />Laboratory parameters<br />Comparisons between aripiprazole and placebo in the proportions of patients experiencing<br />potentially clinically significant changes in routine laboratory and lipid parameters (see<br />section 5.1) revealed no medically important differences. Elevations of CPK (Creatine<br />Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole<br />treated patients as compared to 2.0 % of patients who received placebo.<br />Paediatric population<br />Schizophrenia in adolescents aged 15 years and older<br />In a short-term placebo-controlled clinical trial involving 302 adolescents (13-17 years) with<br />schizophrenia, the frequency and type of undesirable effects were similar to those in adults<br />except for the following reactions that were reported more frequently in adolescents receiving<br />aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):<br />somnolence/sedation and extrapyramidal disorder were reported very commonly (&ge; 1/10), and<br />dry mouth, increased appetite, and orthostatic hypotension were reported commonly (&ge; 1/100,<br />&lt; 1/10). The safety profile in a 26-week open- label extension trial was similar to that<br />observed in the short-term, placebo-controlled trial.<br />The safety profile of a long-term, double-blind placebo controlled trial was also similar except<br />for the following reactions that were reported more frequently than paediatric patients taking<br />placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported<br />commonly (&ge; 1/100, &lt; 1/10).<br />In the pooled adolescent schizophrenia population (13-17 years) with exposure up to 2 years,<br />incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 29.5<br />% and 48.3 %, respectively. In the adolescent (13- 17 years) schizophrenia population with<br />aripiprazole exposure of 5 to 30 mg up to 72 months, incidence of low serum prolactin levels<br />in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 25.6 % and 45.0 %, respectively.<br />In two long term trials with adolescent (13-17 years) schizophrenia and bipolar patients treated<br />with aripiprazole, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt;2<br />ng/ml) was 37.0 % and 59.4 %, respectively.<br />Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older<br />The frequency and type of undesirable effects in adolescents with Bipolar I Disorder were<br />similar to those in adults except for the following reactions: very commonly (&ge; 1/10)<br />somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8<br />%); and commonly (&ge; 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight<br />increased, increased appetite, muscle twitching, and dyskinesia.<br />The following undesirable effects had a possible dose response relationship; extrapyramidal<br />disorder (incidences were 10 mg, 9.1 %, 30 mg, 28.8 %, placebo, 1.7 %,); and akathisia<br />(incidences were 10 mg, 12.1 %, 30 mg, 20.3 %, placebo, 1.7 %).<br />Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for<br />aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.<br />In the paediatric population somnolence and fatigue were observed more frequently in patients<br />with bipolar disorder compared to patients with schizophrenia.<br />In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of<br />low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 28.0 % and 53.3<br />%, respectively.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via:<br />To report any side effect(s):<br />&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms<br />In clinical trials and post-marketing experience, accidental or intentional acute overdose of<br />aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260<br />mg with no fatalities. The potentially medically important signs and symptoms observed<br />included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and<br />diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in<br />children have been received with no fatalities. The potentially medically serious signs and<br />symptoms reported included somnolence, transient loss of consciousness and extrapyramidal<br />symptoms.<br />Management of overdose<br />Management of overdose should concentrate on supportive therapy, maintaining an adequate<br />airway, oxygenation and ventilation, and management of symptoms. The possibility of<br />multiple medicinal product involvement should be considered. Therefore cardiovascular<br />monitoring should be started immediately and should include continuous electrocardiographic<br />monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose<br />with aripiprazole, close medical supervision and monitoring should continue until the patient<br />recovers.<br />Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole<br />Cmax by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in<br />the treatment of overdose.<br />Haemodialysis<br />Although there is no information on the effect of haemodialysis in treating an overdose with<br />aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole<br />is highly bound to plasma proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antipsychotics, ATC code: N05AX12 Mechanism of action<br />It has been proposed that aripiprazole&#39;s efficacy in schizophrenia and Bipolar I Disorder is<br />mediated through a combination of partial agonism at dopamine D2 and serotonin HT1A<br />receptors and antagonism of serotonin 5-HT2A receptors. Aripiprazole exhibited antagonist<br />properties in animal models of dopaminergic hyperactivity and agonist properties in animal<br />models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity in vitro for<br />dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for<br />dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.<br />Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no<br />appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine<br />and serotonin subtypes may explain some of the other clinical effects of aripiprazole.<br />Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for<br />2 weeks produced a dose- dependent reduction in the binding of 11C-raclopride, a D2/D3<br />receptor ligand, to the caudate and putamen detected by positron emission tomography.<br />Clinical efficacy and safety<br />Schizophrenia<br />In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult<br />patients, presenting with positive or negative symptoms, aripiprazole was associated with<br />statistically significantly greater improvements in psychotic symptoms compared to placebo.<br />Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in<br />adult patients who have shown an initial treatment response. In a haloperidol-controlled trial,<br />the proportion of responder patients maintaining response to medicinal product at 52-weeks<br />was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion<br />rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %).<br />Actual scores in rating scales used as secondary endpoints, including PANSS and the<br />Montgomery-Asberg Depression Rating Scale showed a significant improvement over<br />haloperidol.<br />In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia,<br />aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and<br />57 % in placebo.<br />Weight gain<br />In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a<br />26-week, olanzapine- controlled, double-blind, multi-national study of schizophrenia which<br />included 314 adult patients and where the primary end-point was weight gain, significantly<br />less patients had at least 7 % weight gain over baseline (i.e. a gain of at least<br />5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable<br />patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).<br />Lipid parameters<br />In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults,<br />aripiprazole has not been shown to induce clinically relevant alterations in levels of total<br />cholesterol, triglycerides, HDL and LDL.<br />-Total cholesterol: incidence of changes in levels from normal (&lt; 5.18 mmol/l) to high (&ge; 6.22<br />mmol/l) was 2.5 % for aripiprazole and 2.8 % for placebo and mean change from baseline was<br />-0.15 mmol/l (95 % CI: -0.182, -0.115) for aripiprazole and -0.11 mmol/l (95 % CI: -0.148,<br />-0.066) for placebo.<br />-Fasting triglycerides: incidence of changes in levels from normal (&lt; 1.69 mmol/l) to high (&ge;<br />2.26 mmol/l) was 7.4 % for aripiprazole and 7.0 % for placebo and mean change from baseline<br />was -0.11 mmol/l (95 % CI: -0.182, -0.046) for aripiprazole and -0.07 mmol/l (95 % CI:<br />-0.148, 0.007) for placebo.<br />-HDL: incidence of changes in levels from normal (&ge; 1.04 mmol/l) to low (&lt; 1.04 mmol/l) was<br />11.4 % for aripiprazole and<br />12.5 % for placebo and mean change from baseline was -0.03 mmol/l (95 % CI: -0.046, -0.017)<br />for aripiprazole and -0.04 mmol/l (95 % CI: -0.056, -0.022) for placebo.<br />-Fasting LDL: incidence of changes in levels from normal (&lt; 2.59 mmol/l) to high (&ge; 4.14<br />mmol/l) was 0.6 % for aripiprazole and 0.7 % for placebo and mean change from baseline was<br />-0.09 mmol/l (95 % CI: -0.139, -0.047) for aripiprazole and -0.06 mmol/l (95 % CI: -0.116,<br />-0.012) for placebo.<br />Prolactin<br />Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The<br />incidence of hyperprolactinaemia or increased serum prolactin in patients treated with<br />aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole,<br />the median time to onset was 42 days and median duration was 34 days.<br />The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with<br />aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients<br />receiving aripiprazole, the median time to onset was 30 days and median duration was 194<br />days.<br />Manic episodes in Bipolar I Disorder<br />In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a<br />manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to<br />placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or<br />without psychotic features and with or without a rapid-cycling course.<br />In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a<br />manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior<br />efficacy to placebo.<br />In two 12-week, placebo- and active-controlled monotherapy trials in patients with a manic or<br />mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole<br />demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable<br />to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion<br />of patients in symptomatic remission from mania as lithium or haloperidol at week 12.<br />In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of<br />Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to<br />lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of<br />aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic<br />symptoms than lithium or valproate monotherapy.<br />In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who<br />achieved remission on aripiprazole during a stabilization phase prior to randomization,<br />aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily<br />in preventing recurrence into mania but failed to demonstrate superiority over placebo in<br />preventing recurrence into depression.<br />In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of<br />Bipolar I Disorder who achieved sustained remission (Y-MRS and MADRS total scores &le; 12)<br />on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive<br />weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased<br />risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard<br />ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to<br />demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive<br />aripiprazole demonstrated superiority over placebo on the secondary outcome measure,<br />CGI-BP Severity of Illness score (mania). In this trial, patients were assigned by investigators<br />with either open-label lithium or valproate monotherapy to determine partial non-response.<br />Patients were stabilised for at least 12 consecutive weeks with the combination of<br />aripiprazole and the same mood stabilizer.<br />Stabilized patients were then randomised to continue the same mood stabilizer with<br />double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the<br />randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo<br />+ valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive<br />treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate<br />compared to 45 % in placebo + lithium and 19 % in placebo + valproate.<br />Paediatric population<br />Schizophrenia in adolescents<br />In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13-17<br />years), presenting with positive or negative symptoms, aripiprazole was associated with<br />statistically significantly greater improvements in psychotic symptoms compared to placebo.<br />In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing<br />74 % of the total enrolled population, maintenance of effect was observed over the 26-week<br />open- label extension trial.<br />In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects<br />(n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference<br />in the rate of relapse of psychotic symptoms between the aripiprazole (19.39%) and placebo<br />(37.50%) groups. The point estimate of the hazard ratio (HR) was 0.461 (95% confidence<br />interval, 0.242-0.879) in the full population. In subgroup analyses the point estimate of the HR<br />was<br />0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age.<br />However, the estimation of the HR for the younger (13-14 years) group was not precise,<br />reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12),<br />and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow<br />conclusions to be drawn on the presence of a treatment effect. In contrast the 95% confidence<br />interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to<br />0.879 and hence a treatment effect could be concluded in the older patients.<br />Manic episodes in Bipolar I Disorder in children and adolescents<br />Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and<br />adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or<br />mixed episodes with or without psychotic features and had a Y- MRS score &ge; 20 at baseline.<br />Among the patients included in the primary efficacy analysis, 139 patients had a current<br />co-morbid diagnosis of ADHD.<br />Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the<br />Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more<br />pronounced in the patients with associated co-morbidity of ADHD compared to the group<br />without ADHD, where there was no difference from placebo. Recurrence prevention was not<br />established.<br />Table 1: Mean improvement from baseline YMRS score by psychiatric comorbidity<br />Psychiatric<br />comorbidities Week 4 Week 12<br />ADHD<br />Week 4 Week 12<br />Zinole 10 mg<br />(n = 48)<br />14.9 15.1<br />Zinole 10 mg<br />(n = 44)<br />15.2 15.6<br />Zinole 30 mg<br />(n = 51)<br />16.7 16.9<br />Zinole 30 mg<br />(n = 48)<br />15.9 16.7<br />Placebo<br />(n = 52)a<br />7.0 8.2<br />Placebo<br />(n = 47)b<br />6.3 7.0<br />No psychiatric<br />comorbidities Week 4 Week 12<br />No ADHD<br />Week 4 Week 12<br />Zinole 10 mg<br />(n = 27)<br />12.8 15.9 Zinole 10 mg<br />(n = 37)<br />12.7 15.7<br />Zinole 30 mg<br />(n = 25)<br />Zinole 30 mg<br />15.3 14.7 (n = 30) 14.6 13.4<br />Placebo<br />(n = 18)<br />9.4 9.7<br />Placebo<br />(n = 25)<br />9.9 10.0<br />a n = 51 at Week 4<br />b n = 46 at Week 4<br />The most common treatment-emergent adverse events among patients receiving 30 mg were<br />extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1<br />%). Mean weight gain in the 30 weeks treatment- interval was 2.9 kg as compared to 0.98 kg<br />in patients treated with placebo.<br />Irritability associated with autistic disorder in paediatric patients (see section 4.2)<br />Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled<br />trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one<br />52-week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5<br />mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose.<br />Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically<br />superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability<br />subscale. However, the clinical relevance of this finding has not been established. The safety<br />profile included weight gain and changes in prolactin levels. The duration of the long-term<br />safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum<br />prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) in aripiprazole-treated patients<br />was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the<br />mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.<br />Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a<br />13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were<br />either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier<br />relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for<br />relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant<br />difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole<br />was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for<br />placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms<br />were mainly reported during the stabilisation phase in 17 % of patients, with tremor<br />accounting for 6.5 %.<br />Tics associated with Tourette&#39;s disorder in paediatric patients (see section 4.2)<br />The efficacy of aripiprazole was studied in paediatric subjects with Tourette&#39;s disorder<br />(aripiprazole: n = 99, placebo: n =<br />44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose<br />weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a<br />starting dose of 2 mg. Patients were 7 - 17 years of age and presented an average score of 30<br />on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline.<br />Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of<br />13.35,for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20<br />mg) as compared with an improvement of 7.09 in the placebo group.<br />The efficacy of aripiprazole in paediatric subjects with Tourette&#39;s syndrome (aripiprazole: n =<br />32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day<br />and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study<br />conducted in South-Korea. Patients were 6 - 18 years and presented an average score of 29 on<br />TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS<br />change from baseline to week 10 as compared with an improvement of 9.62 in the placebo<br />group.<br />In both of these short term trials, the clinical relevance of the efficacy findings has not been<br />established, considering the magnitude of treatment effect compared to the large placebo effect<br />and the unclear effects regarding psycho-social functioning. No long term data are available<br />with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.<br />The European Medicines Agency has deferred the obligation to submit the results of studies<br />with aripiprazole in one or more subsets of the paediatric population in the treatment of<br />schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information<br />on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours<br />after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral<br />bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the<br />pharmacokinetics of aripiprazole.<br />Distribution<br />Aripiprazole is widely distributed throughout the body with an apparent volume of distribution<br />of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations,<br />aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding<br />primarily to albumin.<br />Biotransformation<br />Aripiprazole is extensively metabolised by the liver primarily by three biotransformation<br />pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies,<br />CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of<br />aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant<br />medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the<br />active metabolite, represents about 40 % of aripiprazole AUC in plasma.<br />Elimination<br />The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive<br />metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.<br />The total body clearance of aripiprazole is 0.7 ml/min/kg, which is primarily hepatic.<br />Following a single oral dose of [14C]-labelled aripiprazole, approximately 27 % of the<br />administered radioactivity was recovered in the urine and approximately 60 % in the faeces.<br />Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 %<br />was recovered unchanged in the faeces.<br />Pharmacokinetics in special patient groups<br />Paediatric population<br />The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17<br />years of age were similar to those in adults after correcting for the differences in body<br />weights.<br />Elderly<br />There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and<br />younger adult subjects, nor is there any detectable effect of age in a population<br />pharmacokinetic analysis in schizophrenic patients.<br />Gender<br />There are no differences in the pharmacokinetics of aripiprazole between healthy male and<br />female subjects nor is there any detectable effect of gender in a population pharmacokinetic<br />analysis in schizophrenic patients.<br />Smoking<br />Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects<br />from smoking on the pharmacokinetics of aripiprazole.<br />Race<br />Population pharmacokinetic evaluation showed no evidence of race-related differences on the<br />pharmacokinetics of aripiprazole.<br />Renal impairment<br />The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be<br />similar in patients with severe renal disease compared to young healthy subjects.<br />Hepatic impairment<br />A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A,<br />B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of<br />aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C<br />liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to<br />reproduction and development.<br />Toxicologically significant effects were observed only at doses or exposures that were<br />sufficiently in excess of the maximum human dose or exposure, indicating that these effects<br />were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical<br />toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104<br />weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum<br />recommended human dose) and increased adrenocortical carcinomas and combined<br />adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean<br />steady-state AUC at the maximum recommended human dose). The highest nontumorigenic<br />exposure in female rats was 7 times the human exposure at the recommended dose.<br />An additional finding was cholelithiasis as a consequence of precipitation of sulphate<br />conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral<br />dosing at 25 to 125 mg/kg/day (1 to 3 times the mean steady- state AUC at the maximum<br />recommended clinical dose or 16 to 81 times the maximum recommended human dose based<br />on mg/m2). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in<br />human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile<br />concentrations found in the monkeys in the 39-week study and are well below (6 %) their<br />limits of in vitro solubility.<br />In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was<br />comparable to that observed in adult animals, and there was no evidence of neurotoxicity or<br />adverse reactions on development.<br />Based on results of a full range of standard genotoxicity tests, aripiprazole was considered<br />non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies.<br />Developmental toxicity, including dose-dependent delayed foetal ossification and possible<br />teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based<br />on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state<br />AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses<br />similar to those eliciting developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinole 15 mg tablets<br />Lactose monohydrate<br />Maize starch pregelatinized<br />Povidone<br />Microcrystalline cellulose<br />Croscarmellose sodium<br />Magnesium stearate<br />Yellow iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinole 15 mg tablets: Aluminium /Aluminium foil blisters in cartons of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi,10. Polígono Industrial Areta,
31620 Huarte-Pamplona (Navarra) – Spain
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>